High Potency Active Pharmaceutical Ingredients Market-Trends, Outlook and Opportunity Analysis 2017-2025
High Potency Active Pharmaceutical Ingredients Market Taxonomy
By Synthesis Route
By Drug Type
By Manufacturer Type
Contract Research Manufacturers
By Therapeutic Applications
Growing demand for Antibody Drug Conjugates (ADC) is expected to augment market growth
Request For Sample Copy@
High potency active pharmaceutical ingredients is considered as a growing area for pharmaceutical manufacturers and contract manufacturing organizations (CMOs) with much R&D focusing on more specialized medicines especially in the field of oncology. According to IMS institute of healthcare informatics, 2016, 586 drugs are under development for oncology treatment, with over 70 new cancer treatments (for over 20 tumor types), entering the market over the past five years (2010-2015). HPAPIs are also increasingly being used in the form of Antibody Drug Conjugates (ADCs), which is an important and effective breakthrough in cancer treatment. However, high capital costs associated with the specialized containment technology required to protect both employees and the environment, as well as lack of harmonization in GMP regulations preventing cross contamination in some countries may hamper growth of the high potency active pharmaceutical ingredients market.
Increasing investment in research and development by manufacturers is expected to propel high potency active pharmaceutical ingredients market growth
Increasing number of major pharmaceutical companies are continuously focusing on expansion of their product line in HPAPIs or considering investing in new HPAPIs production facilities, further outsourcing the manufacturing of HPAPIs to contract manufacturers. This in turn will increase the benefits from the latter’s competency and expertise, as captive manufacturing of HPAPIs is expensive and requires stringent safety and handling specifications. This is thus expected to boost growth of the high potency active pharmaceutical ingredients market. The outsourcing of HPAPIs manufacturing is increasing in India, China, and Eastern European countries due to the low cost of manufacturing as compared to North America and Western Europe regions. For instance, in Oct 2017, Piramal Pharma Solutions (PPS), a contract development and manufacturing organization invested US$ 55 million across its sites in Asia, to expand its API manufacturing capabilities and capacities. Furthermore, companies such as Evonik and Lonza are actively involved in providing contract manufacturing services to other companies.
Among regions, North America holds the largest market share, followed by Europe in the global high potency active pharmaceutical ingredients market. The dominance of this region is due to high prevalence rate of cancer in the region, which in turn is increasing the potential of oncology drugs. For instance, according to an American Cancer Society estimations, 2017, 1,688,780 people are estimated to be diagnosed with cancer and 600,920 cancer deaths are estimated to occur in the US. Furthermore, increasing incidence of age related diseases associated with changing lifestyle and eating habits is also expected to boost growth of the high potency active pharmaceutical ingredients market. As the nature and extents of HPAPIs is different for the ageing population than that for a younger population thus, HPAPIs have become a mitigating factor in reducing the disease burden especially in geriatric population. According to the U.S. census bureau, 2014, 46.2 million people aged 65 years and above, accounted for 14.5% of the total population, which is projected to be 98.2 million by 2060. Moreover, market in Asia Pacific is also gaining significant traction, owing to growing API manufacturing sectors in countries such as China and India, due to expansion of low cost manufacturing facilities by manufacturers/CMOs to produce generic HPAPIs.
Key players in the high potency active pharmaceutical ingredients market include Lonza, Novartis International AG, BASF AG, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics., Boehringer Ingelheim, Covidien Plc, Merck & Co, Bayer AG, Sigma-Aldrich Corporation, and Sanofi Aventis.
Get More Details On this Report:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release High Potency Active Pharmaceutical Ingredients Market-Trends, Outlook and Opportunity Analysis 2017-2025 here
News-ID: 961399 • Views: 263
More Releases from Pharamceutical
Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin …
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these
New improved medication with lesser side effects will drive the insomnia therape …
Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period. Intermezzo (2014), are used in small doses and administered
Antiepileptic Drugs Market - Global Industry Insights,
Antiepileptic Drugs Market Regional Analysis North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast
More Releases for API
Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles. Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform. Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The